Improving access to new breast cancer drugs

Improving access to new breast cancer drugs

When I first started volunteering with METUPUK, I wasn’t really sure what I would do. For a few months, I sat on the sides to get a feel for the organisation. I shared METUPUK links on social media, but I don’t have much of a social media presence, and Instagram is a bit of a mystery to me. I’ve never figured out how to do makeup, plus my hair is a non-event after chemo. I thought I wanted to help with drug access or access to clinical trials, but I was flexible and wanted to see what was needed.

On the trail of a Clinical Trial…

On the trail of a Clinical Trial…

METUPUK historically maintained their own in-house clinical trial database for metastatic trials in the UK as there was no one source that contained them all. It used the key sites used across the UK; Cancer Research UK, Be Part of Research, ISRCTN and ClinicalTrials.gov.

Leaping forward to 2022, surely by now one of them must be THE accurate, easily searchable source of breast cancer trials? If not, how do our oncologists quickly and accurately find the best trials for their metastatic patients?

And where do patients start when looking for a metastatic trial themselves?

Why we need MBC research more than ever

Why we need MBC research more than ever

At METUPUK, we dream of the day when metastatic breast cancer (MBC) is downgraded from an incurable to a chronic illness. The only way this will be possible is through new scientific research. We urgently need more research into this deadly disease.
We need more clinical research into MBC, including clinical trials. These are crucial for determining which are the most effective treatment options and for bringing new drug treatments to patients.

What does METUPUK do?

MetUpUK

METUPUK is now 5 years old. 

In those 5 years there haven’t been many changes in our plans from what we set out to do, but we have achieved so much! And we are now a registered charity!

Our strategy, aims and objectives are the same as when we started, we knew what direction we were going in but we are now looking to demand more action and accountability for patients.

Trodelvy is approved by the Scottish Medicines Consortium (SMC) for Metastatic Triple Negative Breast Cancer for use by NHS Scotland

Trodelvy is approved by the Scottish Medicines Consortium (SMC) for Metastatic Triple Negative Breast Cancer for use by NHS Scotland

METUPUK welcomes the Scottish Medicines Consortium (SMC) acceptance of Trodelvy® (sacituzumab govitecan) for use within NHSScotland.

Trodelvy is an innovative drug which has been accepted for the treatment metastatic triple-negative breast cancer (mTNBC) within NHSScotland.  Metastatic triple-negative breast cancer is a challenging disease to treat, and an even more devastating disease to live with.